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Aim: To investigate which metabolic pathways are targeted by the sodium-glucose
co-transporter-2 inhibitor dapagliflozin to explore the molecular processes involved
in its renal protective effects.
Methods: An unbiased mass spectrometry plasma metabolomics assay was per-
formed on baseline and follow-up (week 12) samples from the EFFECT II trial in
patients with type 2 diabetes with non-alcoholic fatty liver disease receiving
dapagliflozin 10 mg/day (n = 19) or placebo (n = 6). Transcriptomic signatures from
tubular compartments were identified from kidney biopsies collected from patients
with diabetic kidney disease (DKD) (n = 17) and healthy controls (n = 30) from the
European Renal cDNA Biobank. Serum metabolites that significantly changed after
12 weeks of dapagliflozin were mapped to a metabolite-protein interaction network.
These proteins were then linked with intra-renal transcripts that were associated
with DKD or estimated glomerular filtration rate (eGFR). The impacted metabolites
and their protein-coding transcripts were analysed for enriched pathways.
Results: Of all measured (n = 812) metabolites, 108 changed (P < 0.05) during
dapagliflozin treatment and 74 could be linked to 367 unique proteins/genes. Intra-
renal mRNA expression analysis of the genes encoding the metabolite-associated
proteins using kidney biopsies resulted in 105 genes that were significantly associ-
ated with eGFR in patients with DKD, and 135 genes that were differentially
expressed between patients with DKD and controls. The combination of metabolites
and transcripts identified four enriched pathways that were affected by dapagliflozin
and associated with eGFR: glycine degradation (mitochondrial function), TCA cycle II
(energy metabolism), L-carnitine biosynthesis (energy metabolism) and superpathway
of citrulline metabolism (nitric oxide synthase and endothelial function).
Conclusion: The observed molecular pathways targeted by dapagliflozin and associ-
ated with DKD suggest that modifying molecular processes related to energy
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metabolism, mitochondrial function and endothelial function may contribute to its
renal protective effect.
K E YWORD S
bioinformatics, dapagliflozin, kidney function, metabolomics, sodium-glucose co-transporter-2,
type 2 diabetes
1 | INTRODUCTION
Sodium-glucose co-transporter 2 inhibitors (SGLT2is) are approved
for glucose-lowering treatment of patients with type 2 diabetes.
SGLT2is show beneficial effects on body weight, blood pressure and
albuminuria and reduce the risk of heart failure hospitalization and car-
diovascular (CV) death as well as end-stage renal disease in patients
with diabetic kidney disease (DKD).1-4 The precise underlying mecha-
nisms responsible for these protective effects remain to be resolved.
Although SGLT2is are primarily indicated as glucose-lowering agents,
they have a broad range of effects that could explain the salutary
effects on CV and renal health including effects on energy metabolism,
renal function, electrolyte and plasma volume homeostasis.5-8
Although several theories on the mechanism of action have been
proposed, sophisticated mechanistic studies in humans as well as
unbiased approaches are needed to understand the molecular mecha-
nism underlying the protective effect of SGLT2is on CV and renal
outcomes. To this end, a prior study performed untargeted met-
abolomics, that is, the measurement of low-weight intermediates and
end-products of cellular functions in biological fluids, to investigate the
effect of short-term (4 weeks) treatment with the SGLT2i empagliflozin
on serum metabolites in patients with type 2 diabetes.9 However, this
study only described a subset of metabolites changed during
empagliflozin treatment and did not perform an integrative bioinfor-
matic approach to examine which kidney tissue-associated molecular
pathways may be associated with SGLT2i-altered metabolites.
In the current study, we have used an unbiased high-throughput
metabolomics assay to measure metabolites involved in all major met-
abolic pathways in plasma from patients with type 2 diabetes treated
with dapagliflozin for 12 weeks. We subsequently integrated the
metabolites with transcriptomic features measured in kidney tissues
in a bioinformatic analysis to identify molecular pathways through
which dapagliflozin may exert renal protective effects in order to
improve our understanding of the mechanistic action of dapagliflozin.
2 | MATERIALS AND METHODS
2.1 | Study design
For the current study, all patients with type 2 diabetes treated with
dapagliflozin (n = 19) were selected from the EFFECT II study.10 The
design and primary results of the EFFECT II study were published pre-
viously.10 Briefly, it was a 12-week, multicentre, randomized, placebo-
controlled, double-blind, four-arm, parallel group trial performed at
five clinical research centres at university hospitals in Sweden. Indi-
viduals enrolled in this study were eligible if they had been treated
with a stable dose of metformin or sulphonylurea alone or in combi-
nation for at least 3 months, if they had a liver proton density fat
fraction of >5.5%, which is commonly used as a cut-off for non-
alcoholic liver fatty disease, and a body mass index (BMI) of
>25 kg/m2. Exclusion criteria included the use of SGLTis, insulin or
glucagon-like peptide receptor agonists, or a history of hepatic dis-
ease and creatinine clearance of <60 mL/min (Cockcroft-Gault).
Patients were randomly assigned to dapagliflozin 10 mg/day,
omega-3 carboxylic acids 4 g/day, combined dapagliflozin and
omega-3 carboxylic acids, or matching placebo. For the purpose of
this analysis, data from patients with available samples for met-
abolomics analysis and assigned to dapagliflozin (n = 19) or placebo
(n = 6) were used. The study was approved by the Regional Ethics
Review Board in Uppsala, registered at ClinicalTrial.gov (ClinicalTrial.
gov identifier NCT02279407) and conducted in accordance with the
Declaration of Helsinki and the International Conference on
Harmonisation of Good Clinical Practice. All participants provided
written informed consent before participating.
To link the metabolomics signature derived from the EFFECT II
study to a kidney-specific pathophysiological context, we used cross-
sectional transcriptomics data from patients with DKD (n = 17) and
healthy donors (n = 30) who participated in the European Renal cDNA
Bank-Kroener-Fresenius Biopsy Bank (ERCB) cohort (n = 47). The
study design and characteristics of these participants have been
described previously.11,12
2.2 | Participant characteristics and measurements
In the EFFECT II cohort, patient characteristics were obtained as pre-
viously described.10 Briefly, height and weight were measured with
standard methods in light clothing without shoes and BMI was calcu-
lated as body weight (kg) divided by height (m) squared. Fasting blood
samples were taken in the morning before intake of the investiga-
tional products. HbA1c was determined with ion-exchange high-
performance liquid chromatography (All Variant II and Variant II Turbo
Hemoglobin A1c reagents, Bio-Rad, Hercules, CA).
In the ERCB cohort, fresh renal biopsy samples from patients with
DKD and healthy donors were micro-dissected into glomerular and
tubulointerstitial compartments. RNA was isolated and prepared for
microarray analysis as described previously.11,12
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2.3 | Metabolomic platform
The non-targeted metabolomic analysis was performed at Metabolon
(Morrisville, NC). All plasma samples were stored at −80C until
processed. Fasting plasma samples from baseline (visit 1) and end-of
study (visit 4) were extracted. The samples were extracted with meth-
anol and the supernatants divided into five equal fractions: two for
analysis by two separate reverse phase (RP)/ultra-performance liquid
chromatography-tandem mass spectrometry (UPLC-MS/MS) methods
with positive ion mode electrospray ionization (ESI), optimized for
more hydrophilic and hydrophobic compounds, respectively, one for
analysis by RP/UPLC-MS/MS with negative ion mode ESI, one for
analysis by hydrophilic interaction liquid chromatography/UPLC-MS/
MS with negative ion mode ESI, and one sample was reserved for
backup.13 All methods utilized a Waters ACQUITY UPLC and a
Thermo Scientific Q-Exactive high resolution/accurate mass spec-
trometer interfaced with a heated ESI source and Orbitrap mass ana-
lyser operated at 35 000 mass resolution. The MS analysis alternated
between MS and data-dependent MSn scans using dynamic exclusion.
The scan range varied slightly between methods but covered
70-1000 m/z. Compounds were identified by comparison with stan-
dard library entries of purified standards or recurrent unknown enti-
ties based on retention time, molecular weight, preferred adducts and
in-source fragments, as well as associated MS spectra, and were
curated by visual inspection for quality control using proprietary soft-
ware developed by Metabolon. The method by which each metabolite
is quantitated was dependent on factors such as interference by
neighbouring peaks and reproducibility/variability. The quantitation
was performed by proprietary software that matched ions to an in-
house library of standards for metabolite identification followed by
metabolite quantitation by peak area integration.14
2.4 | Statistical analysis
Before analysis, the metabolic dataset was imputed with the lowest
observed value in the sample for that metabolite. All values were
median scaled and before analysis were transformed using the natural
logarithm. Changes in metabolites were primarily evaluated in a uni-
variate fashion. To determine whether metabolites had significantly
changed, paired t-tests were used on the difference between baseline
and end of study in logarithmic scale. The results of the paired t-tests
are presented as geometric mean ratios and P-values. No adjustment
for multiplicity was performed because of the hypothesis-generating
nature of the study; instead we evaluated the results based on a path-
ophysiological context and pathway analysis using the significant
changes from the paired t-test. A P-value below 0.05 was regarded as
significant. The changes in metabolites were also adjusted for changes
in fasting plasma glucose by looking at the intercept of a linear regres-
sion model with change in the logarithm of glucose as a covariate. In
an additional analysis, the effect of dapagliflozin compared with pla-
cebo on the change in the metabolite from baseline was also assessed
by an analysis of covariance model (ANCOVA) with treatment and
baseline measurement as covariates. Because of the small sample size
of the placebo group, a P-value of ≤0.1 was adopted to indicate statis-
tical significance. A sensitivity analysis was performed by adding an
interaction term in the ANCOVA. All statistical analyses were per-
formed with R version 3.3.3 to 3.5.2 (R Project for Statistical Comput-
ing, www.r-project.org). A schematic overview of the multi-omics
approach to identify molecular pathways associated with progressive
kidney function decline is shown in Figure 1. All metabolomic features
were used for analyses as there were no missing values. The human
metabolite database (HMDB) version 4.0 was used to select related
genes. Significant metabolites (ρ ≤ 0.05) identifiable by an HMDB
identifier were used for mapping and pathway analysis. To link these
metabolomic molecular features to a kidney-specific pathophysiologi-
cal context, all significant metabolomic molecular features that could
be mapped to a gene were subsequently associated with kidney
biopsy-derived transcriptomic features. SGLT2i-induced changes in
metabolome were probably affecting the high energy-demanding
tubules, making it a probable candidate for cross-omics integration.
To select the transcripts, we used the annotated protein-metabolite
interactions in the HMDB and selected protein-coding transcripts.
The selected transcriptomic features were used for the pathway inte-
gration if they either correlated with the estimated glomerular filtra-
tion rate (eGFR) assessed by Pearson correlation in patients with
DKD, or when they were differentially expressed between healthy liv-
ing donors without diabetes or chronic kidney disease and patients
with DKD, as assessed by Student's t-test (Figure 1).
Ingenuity pathway analysis (QIAGEN) version 01–14 software
was used to assign enriched pathways from the selected molecular
metabolic or transcriptomic features using Fischer's exact test. The
significantly enriched pathways (P < 0.05) based on transcriptomic or
metabolomics features were compared. The set pathways identified
by overlapping significant pathways from both metabolites and tran-
scripts were used as a probable mechanism, on a mechanistic molecu-
lar level, for how dapagliflozin can attenuate kidney function decline.
3 | RESULTS
3.1 | Participants
The participants in the EFFECT II study had an average age of
64.7 years and were all overweight or obese (Table 1). At baseline, the
mean diabetes duration was 4.7 years. Most individuals were treated
with metformin alone (58%) or in combination with sulphonylurea
(21%), 16% were drug-naïve and one patient was treated with sul-
phonylurea alone (5%). No change in medication occurred during the
study period. Mean HbA1c was 56 mmol/mol or 7.3%. As previously
reported, dapagliflozin treatment decreased body weight by 3%
(P < 0.05) and fasting glucose by 10% (P < 0.05) from baseline.9 In the
ERCB cohort, participants with DKD had a lower eGFR compared
with living donors and EFFECT II participants (Table 1).
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3.2 | Metabolomic profiles
A total of 1216 metabolites were measured, including 812 identified
metabolites and 404 which were unknown. The paired t-test evaluat-
ing differences between baseline and week 12 in the dapagliflozin
treatment arm identified 108 metabolites that significantly changed,
of which 22 metabolites were significantly increased and 86 were sig-
nificantly reduced (Tables S1 and S2). In order to understand how the
reduction of glucose could have influenced the metabolites, the
changes in metabolites were also adjusted for changes in glucose
(Tables S1 and S2). An additional analysis was performed to examine
the effect of dapagliflozin compared with placebo on the metabolites.
Fourteen metabolites increased compared with placebo while
16 metabolites decreased compared with placebo (Tables S1 and S2).
The subsequent presentation and analyses are based on the
placebo unadjusted metabolite changes during dapagliflozin treat-
ment. Metabolites belonging to the superpathway of amino acids
were largely over-represented among the metabolites that
significantly increased and constituted more than 80% of the identi-
fied metabolites, while the remaining metabolites belonged to the
superpathways of xenobiotics, carbohydrates and co-factors and vita-
mins (Table S1). The most significant was N-acetyl aspartate (NAA),
which is uniquely synthesized by neuronal mitochondria.15 An
increase in carnitines derived from partly metabolized branch chain
amino acids (BCAAs) (isobutyryl-, isovaleryl- and tiglylcarnitines) was
observed, while the levels of the corresponding amino acids did not
change. Three out of the 22 metabolites identified as significantly
increased by SGLT2is belonged to the sub-pathway of histidine
metabolism. Plasma levels of urea as well as four other metabolites,
including N6-N6-N6-trimethyllysine and arginate, belonging to the
urea cycle sub-pathway, were increased. Plasma levels of creatine,
sarcosine and heme also increased.
Among the metabolites that were reduced, lipids were over-
represented and constituted >50% of the downregulated identified
metabolites (Table S2). Lipid species from several different lipid clas-
ses were reduced, including diacylglycerols, endocannabinoids,
F IGURE 1 Schematic overview of a metabolomics to intra-renal transcriptomics approach to identify molecular pathways targeted by
dapagliflozin and associated with progressive kidney function decline. (A) Metabolomics were performed in the EFFECT II randomized controlled
trial. (B) Metabolites changed during dapagliflozin were identified. (C) To link the metabolomic features with kidney-specific pathophysiology,
unique protein-coding genes derived from metabolomic features that significantly changed during dapagliflozin treatment were identified, and the
gene expression profiles measured in kidney tissues from ERCB participants representing these genes were selected. (D) The gene expressions
were then associated with estimated glomerular filtration rate decline, and significant features were selected. (E) Pathway analysis was then
performed based on selected metabolomics and transcriptomic features, and (F) integration analysis of enriched molecular pathways based on
metabolites and intra-renal transcripts was performed to select molecular pathways targeted by dapagliflozin and associated with diabetic kidney
disease progression. ERCB, European Renal cDNA Bank-Kroener-Fresenius Biopsy Bank
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dicarboxylic acids and monohydroxylated, mainly 3-hydroxylated, fatty
acids. A marked reduction in a dihydroxy fatty acid, 12, 13-HOME, was
also observed. Interestingly, several primary and secondary bile acids
were reduced, indicating reduced bile acid pool. As expected, treatment
reduced plasma glucose levels and other simple carbohydrates. The
change in fasting glucose correlated well with the quantitative changes
in fasting glucose measured previously (ρ = 0.79, P < 0.0001). As previ-
ously observed, plasma levels of urate were reduced.5 Three metabolites
in xanthine metabolism including theophylline, which is upstream urate
in purine degradation, were reduced. Alanine and glutamine were the
only amino acids reduced in plasma. Intermediates in the TCA cycle,
including succinate, fumarate and malate, were reduced.
3.3 | Metabolomics to transcriptomics linkage
As a next step, we took advantage of our database containing trans-
criptomic profiles derived from micro-dissected tubulointerstitial com-
partments of patients' biopsies and corresponding eGFR. The aim was
to identify early effects of dapagliflozin on kidney function by corre-
lating changes associated with DKD with effects of dapagliflozin in
the diabetic EFFECT II patients with normal eGFR. To link the metabo-
lites to a kidney-specific pathophysiological context, the metabolomic
molecular features that significantly changed during dapagliflozin
treatment and could be linked to a gene were subsequently associ-
ated with kidney biopsy-derived transcriptomic features. The number
of metabolites and transcripts that were selected for pathway identi-
fication are shown in Table 2. Of the 812 measured metabolites,
535 metabolites could be linked to a known HMDB identifier. Of
these identified metabolites, 74 (Tables S1 and S2) were significantly
changed by dapagliflozin and were mapped to proteins. Because a
single metabolite can be derived from multiple proteins, the 74 known
metabolites resulted in 367 unique proteins with corresponding
protein-coding gene (Table 2). To link these proteins to molecular sig-
natures within a kidney-specific context, genes were selected from
the same proteins that were associated with the metabolomics
molecular features that changed upon dapagliflozin treatment. The
expression value of these genes was then extracted from trans-
criptomic data derived from micro-dissected tubulointerstitial com-
partments of patients' biopsies. Of the 367 selected tubular protein-
coding genes, 292 passed quality control. Linear regression analyses
and differential expression analysis subsequently showed that
105 genes were significantly associated (P < 0.05) with eGFR in
patients with DKD (n = 17) and 135 genes were differentially
expressed (P < 0.05) between DKD (n = 17) and healthy donors
(n = 30) (Table 2).
TABLE 1 Baseline characteristics from the EFFECT II and ERCB cohorts
EFFECT II ERCBa
Dapagliflozin (n = 19) Placebo (n = 6) Living donor (n = 30) Diabetic kidney disease (n = 17)
Age, years 64.7 (6.6) 64.7 (6.9) 48 (12) 58 (10)
Sex
Male 14 3 15 12
Female 5 3 15 5
BMI, kg/m2 30.5 (2.9) 30.7 (2.2)
Diabetes duration, years 4.7 (9.3) 7.2 (7.0)
HbA1c, % 7.3 (0.5) 7.9 (0.6)
Cholesterol, mmol/L 4.9 (1.0) 4.2 (1.2)
Triglycerides, mmol/L 2.1 (1.2) 2.2 (1.0)
Diastolic blood pressure, mmHg 86.2 (7.8) 84.6 (6.2)
Systolic blood pressure, mmHg 147.3 (12.2) 136.2 (6.7)
eGFR, mL/min per 1.732 86.5 (11.2) 87.7 (11.9) 106.2 (30.9) 44.3 (24.9)
Diabetes medication
Metformin, n (%) 11 (58%) 4 (67%)
Sulphonylurea, n (%) 1 (5%) 0 (0%)
Metformin + sulphonylurea, n (%) 4 (20%) 1 (17%)
None/other, n (%) 3 (16%) 1 (17%)
Hypertension medication
ACEi, n (%) 8 (42%) 1 (17%)
ARB, n (%) 6 (32%) 3 (50%)
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; eGFR, estimated glomerular
filtration rate; ERCB, European Renal cDNA Bank-Kroener-Fresenius Biopsy Bank.
aClinical chemistry and diabetes medications were not recorded in the ERCB cohort.
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3.4 | Pathway analysis
Pathway selection occurred on the basis of the overlap between the
enriched pathways derived from selected transcriptomic and met-
abolomics features. At the pathway level, enrichment analysis of the
significantly deregulated metabolites resulted in seven metabolic
pathways (Figure 2). Four of these pathways were also significantly
enriched in the transcriptome and resulted in 15 unique genes and
11 metabolites of interest (Table 3, Figure 3). Thus, in total, four
molecular pathways associated with dapagliflozin and DKD were
identified based on the overlap between metabolomic- and
transcriptomic-derived pathways (Figure 3). The bioinformatic analysis
revealed that dapagliflozin upregulated the superpathway of citrulline
metabolism, as well as the TCA cycle II, and the L-carnitine biosynthesis
pathways, and seemed to decrease the glycine degradation (creatine bio-
synthesis) pathway. When comparing dapagliflozin with placebo treat-
ment, metabolites included in the superpathway of citrulline metabolism
and the glycine degradation pathway were significantly different, while
metabolites in the TCA cycle II and L-carnitine pathways were not signif-
icantly different between the groups.
4 | DISCUSSION
In this study, we investigated the effect of 12 weeks of treatment of
dapagliflozin, an SGLT2i, on plasma levels of more than 800 identified
metabolites. In general, our results show that treatment of
dapagliflozin in the fasting situation is associated with increased
amino acid metabolites and reduced levels of lipid species from sev-
eral subclasses. We used a bioinformatic approach to delineate molec-
ular pathways that may contribute to the renal protective effects of
the SGLT2i dapagliflozin. Overlap at the gene expression level
between metabolites targeted by dapagliflozin and intra-renal
transcripts associated with DKD pointed to upregulation of the
TABLE 2 Summary of feature selection. The number of features measured and associated with dapagliflozin and diabetic kidney disease
(DKD) are shown for metabolomic and transcriptomic features
Features measured (n)a Features selected (n)b Unique compounds (n)c Unique protein-coding genes
Metabolomics
SGLT2i 812 108 74 367
Transcriptomics
Tubular cross sectional eGFR 292 105 105 105
Tubular DN vs. healthy 292 135 135 135
Abbreviations: DN, diabetic nephropathy; eGFR, estimated glomerular filtration rate; SGLT2i, sodium-glucose co-transporter 2 inhibitor.
aNumber of features that could be measured using the assay.
bIdentifiable features by univariate analysis or machine learning.
cUnique identifiable features by univariate analysis or machine learning.
F IGURE 2 Pathways
significantly enriched in features
based on metabolites affected
by dapagliflozin. Significant
genes (green, left column)
derived from the renal tissue
transcriptomics and associated
with estimated glomerular
filtration rate or significantly
different between patients with
diabetic kidney disease and
healthy donors are shown.
Metabolites which significantly
changed during dapagliflozin
and represented in the enriched
pathways are shown in red on
the right side of the figure. In
the middle, enriched pathways
based on the metabolites are
shown in blue, with the bold
pathways also having significant
enrichment in the kidney
transcriptome
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superpathway of citrulline metabolism, the TCA cycle II, and L-carnitine
biosynthesis, as well as possibly a downregulation of the glycine degra-
dation pathway (creatine biosynthesis). These molecular pathways are
linked to energy metabolism, mitochondrial function and endothelial
function, suggesting that dapagliflozin treatment may slow the progres-
sion of DKD by altering the activity of these pathways.
In line with previously published metabolomics results based on
1 month of treatment with empagliflozin, several of the increased






correlation with eGFR in DKD
Difference in transcripts between
DKD and healthy control
Superpathway of citrulline
metabolism
Fumaric acid, L-glutamine, urea GLS2, ASL, GLS ARG2
TCA cycle II Succinic acid, fumaric acid, L-malic acid SDHB, FH, SDHD, MDH2,
SUCLA2, MDH1, SUCLG1




Creatine, guanidinoacetate GAMT, GATM GAMT, GATM
L-carnitine biosynthesis N6,N6,N6-trimethyl-L-lysine, succinic acid BBOX1, ALDH9A1 ALDH9A1
Abbreviations: ALDH9A1, aldehyde dehydrogenase 9 family member A1; ARG2, arginase 2; ASL, argininosuccinate lyase; BBOX1, butyrobetaine (gamma)
2-oxoglutarate dioxygenase (gamma-butyrobetaine hydroxylase) 1; DKD, diabetic kidney disease; eGFR, estimated glomerular filtration rate; FH, fumarate
hydratase; GAMT, guanidinoacetate N-methyltransferase; GATM, glycine amidinotransferase (L-arginine: glycine amidinotransferase); GLS, glutaminase;
GLS2, glutaminase 2 (liver, mitochondrial); MDH1, malate dehydrogenase 1 NAD (soluble); MDH2, malate dehydrogenase 2 NAD (mitochondrial); SDHB,
succinate dehydrogenase complex, subunit B, iron sulphur (Ip); SDHD, succinate dehydrogenase complex subunit D integral membrane protein; SUCLA2,
succinate-CoA ligase ADP-forming beta subunit; SUCLG1, succinate-CoA ligase alpha subunit.
*P-values from Fisher exact test for enrichment of each pathway by metabolites were 0.014, 0.016, 0.020 and 0.028 for superpathways of citrulline
metabolism, TCA cycle II, glycine degradataion and L-carnitine biosynthesis, respectively. P-values for enrichment of these pathways by transcripts were
0.039, <0.01, 0.014 and 0.023, respectively.
F IGURE 3 Identified molecular pathway
based on metabolite and intra-renal transcripts
integration. Molecular pathways highlighted in
light orange indicate pathways targeted by
dapagliflozin and associated with diabetic
kidney disease progression
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metabolites belonged to the sub-pathway of BCAA, while the
corresponding BCAAs were not changed.9 Also, urea and urea cycle
metabolites, including N2, N5 diacetylornithine, N-delta-acetylornithine
and argininate, were similarly increased in the two studies. In contrast
to the findings of Kappel et al,9 we observed decreased levels of TCA
metabolites. The reason for the different response is unclear but may
be attributable to many factors such as different populations or treat-
ment durations. Whereas Kappel et al found increased levels of acetyl-,
propionyl- and β-hydroxybutyrylcarnitine, we have observed increased
levels of butyrylcarnitine10 and, in this study, reduced plasma levels of
myristoylcarnitine. When fatty acid oxidation is incomplete, surplus
acyl-groups are exported from mitochondria as acylcarnitines.16
Reduced levels of acylcarnitines could therefore reflect a larger degree
of complete fatty acid oxidation. In contrast to the long-chain
acylcarnitines, fasting increases the release of short-chain carnitines,
including acetylcarnitine and propionylcarnitine from the hepa-
tosplanchnic bed.17 Several 3-hydroxy fatty acids decreased by
dapagliflozin and high levels of these fatty acids are markers of fatty
acid oxidation disorders.18 Together, these results could indicate
improved fatty acid oxidation and an enhanced fasting response with a
surplus of 2- and 4-chain carbons.
Plasma metabolomics have also been investigated in animal
models treated with SGLT2is. Treatment of obese non-diabetic mice
with canagliflozin showed activation of catabolic pathways including
fatty acid oxidation and signs of inhibition of mTOR, while there was
activation of AMPK.19 In another study, the effects of ipragliflozin on
metabolites were investigated in a model of diabetic nephropathy on
Black and Tan BRachyury (BTBR) ob/ob mice.20 In line with our
results, they observed that SGLT2is reduced the high levels of TCA
cycle intermediates in the kidney of BTBR ob/ob mice. Collectively,
findings from these cross-species studies underscore the metabolic
effects of SGLT2is, which may potentially contribute to long-term
clinical benefits.
SGLT2i treatment increases haemoglobin and haematocrit. To what
extent this is secondary to plasma contraction or increased red cell mass
is unknown.21 Heme, an intermediate in haemoglobin metabolism, is one
of the metabolites significantly increased after dapagliflozin treatment.
Increased heme levels could reflect an increased heme synthesis, but also
reduced degradation of heme by heme oxygenase. Reduced plasma
levels of bilirubin could indicate reduced heme degradation because car-
bon oxide and biliverdin, which is further reduced to bilirubin, are the
end-products of heme oxygenase activity.22 Regardless of the exact
underlying mechanism, the increase in heme supports a potential effect
of SGLT2is on haematopoiesis.23
The molecular pathways selected through our bioinformatic
approach have been associated with progressive renal function loss in
patients with type 2 diabetes.24-26 The bioinformatics analysis showed
that dapagliflozin treatment increased the TCA cycle activity. Expres-
sion of several TCA cycle enzymes was associated with increased
eGFR, indicating a positive effect on renal mitochondrial function.
Increased levels of metabolites and intermediates of the TCA cycle
have been associated with DKD and endoplasmatic reticulum
stress.24,27 The cause of the reduced levels of TCA-cycle
intermediates is not clear, but may be explained by improved mito-
chondrial efficacy, as reflected by indications of a larger degree of
complete fatty acid oxidation as well as increased gluconeogenesis,
which may take place both in the liver and the kidney to compensate
for urinary glucose loss. Additional support of the salutary effects on
mitochondrial function is our finding that kynurenine was reduced
while picolinic acid, a product of kynurenine metabolism, increased.
This finding may indicate increased activity of the kynurenine path-
way and increased production of quinolinic acid and NAD+ that may
further support improved mitochondrial function after dapagliflozin
treatment. Also, the increased plasma levels of NAA indicate improved
mitochondrial function, specifically in the brain.15 In line with these
observations, a recent study showed that a metabolite panel previ-
ously associated with reduced mitochondrial function improved after
dapagliflozin in patients with type 2 diabetes and chronic kidney dis-
ease.28 Moreover, studies in experimental animals have shown
improved mitochondrial function both in the heart and renal tubules
following treatment with SGLT2is.29,30 These data together support
the notion that long-term renal protective effects of SGLT2is may be
mediated through amelioration of mitochondrial function.
We also found the superpathway of citrulline metabolism to be
associated with DKD progression and targeted/increased by
dapagliflozin, as evidenced by the increase in urea and reduction in
glutamine. The citrulline pathway involves nitric oxide synthase as
one of the key enzymes which generates citrulline from arginine in a
single reaction step. Nitric oxide synthase-derived nitric oxide exerts a
wide array of effects and acts in the blood vessels as a potent vasodi-
lator, exerting antithrombotic effects, and also has anti-inflammatory
effects.31 Several studies have shown that SGLT2 inhibition in
patients with type 2 diabetes improves endothelial function as mea-
sured by reactive hyperemia peripheral arterial tonometry and flow-
mediated dilation and endothelial dysfunction has been associated
with accelerated renal function decline.32-34 The exact mechanism of
how SGLT2 inhibition improves endothelial function is not fully
understood but may involve improved glycaemic and metabolic con-
trol, osmotic diuresis, and changes in sodium homeostasis as a result
of increased natriuresis. The current study supports a potential role
for improvements in endothelial function, through the citrulline path-
way, as one of the potential mediators of the protective effects of
SGLT2 inhibition on kidney function.
The results of the bioinformatics approach indicated a change in
the glycine degradation pathway after dapagliflozin treatment. De
novo creatine synthesis starts by the conversion of glycine and argi-
nine to ornithine and guanidinoacetate by glycine amidinotransferase
(GATM), and guanidinoacetate is then converted to creatine by
guanidinoacetate N-methyltransferase (GAMT), a reaction which is
dependent on S-adenosylmethionine as methyl donor.35 In this study,
plasma creatine levels increased, while the creatine precursor,
guanidinoacetate, was reduced, indicating increased GAMT activity.
Alternatively, reduced GATM activity explains reduced levels of
guanidinoacetate and therefore increased creatine levels must be
explained by causes other than changed synthesis, such as increased
dietary intake of creatine. Overall, the bioinformatics analysis
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suggested reduced activity of the pathway, although we cannot rule
out the possibility that increased creatine levels are the result of
increased GAMT activity. Therefore, the suggestion of reduced gly-
cine degradation should be carefully interpreted.
In contrast to previous studies, this study combined met-
abolomics and transcriptomics to identify metabolites and pathways
associated with dapagliflozin response. This approach is potentially
applicable in other chronic disease settings and can be used to identify
novel biomarkers for disease progression and drug efficacy and safety
monitoring. The advantage is that the bioinformatic approach incorpo-
rates molecular pathway information associated with disease progres-
sion as well as biomarkers and pathway information associated with
drug response, thereby decreasing the probability of false positive
findings. A limitation is that the bioinformatic approach only includes
molecular features and molecular pathways which have previously
been annotated and does not include novel mechanisms.
The limitations of this study include the small sample size, which
hampers the statistical power of this study as well as the generalizabil-
ity to the broader type 2 diabetes population because the studied
population was a predominantly male Caucasian population. Although
we compared the effect of dapagliflozin with placebo in an additional
analysis, we only considered metabolites which statistically signifi-
cantly changed from baseline during dapagliflozin treatment for fur-
ther integration analysis because the metabolomics profile could only
be determined in six patients in the placebo group. Secondly, the short
follow-up precluded assessment of the effect of dapagliflozin on
eGFR decline. Thirdly, the EFFECT II trial included patients with pre-
served kidney function, whereas tissue renal transcriptomics was per-
formed in patients with preserved or impaired renal function
participating in the ERCB study. It is possible that the effects of
dapagliflozin on the metabolites are different in patients with different
clinical characteristics, demographics and degrees of renal impairment.
Hence, validation of our findings in larger studies with a longer dura-
tion as well as in patients with type 2 diabetes and chronic kidney dis-
ease, such as the DAPA-CKD trial, is required.36 Unfortunately, urine
was not available, which could reveal a more renal specific signal.
Nevertheless, our finding that metabolites related to mitochondrial
function changed was in keeping with another study using urinary
metabolites.25
In conclusion, the molecular pathways targeted by dapagliflozin
and associated with DKD suggest that molecular processes related to
energy metabolism, mitochondrial function and endothelial function
may be involved in the renal protective effects of dapagliflozin. These
data confirm existing and offer novel hypotheses about the molecular
effects of dapagliflozin in slowing the progression of DKD.
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